# Forecyte Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/forecyte-bio

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.forecytebio.com
- Latest round: Series A (Dec 23, 2021)
- Investors on record: 3

## About

Based in Shanghai, China and founded in 2021, Forecyte Bio Limited is a company providing CDMO services in the field of cell and gene therapy. The company's CEO Ms. Yingke He worked in GSK for more than 20 years, and has experience in strategy design, project advancement, resource integration, and team building. The company's CTO Dr. Shuyuan Zhang has nearly 30 years of technical and managerial experience in gene and cell therapy process development and GMP manufacturing. The company's COO Dr. Yujian You has 14 years of business development and marketing experience in the life science field.

The company's business includes plasmid production, viral vector production and  cell therapy production. Its virus species include adeno-associated virus, adenovirus, lentivirus, lysozyme virus, retrovirus, etc. Its cellular products include CAR-T, TCR-T, CAR-NK, etc.

## Funding rounds

- Series A, Dec 23, 2021 — Vertex Ventures Southeast Asia & India, BioTrack Capital, Ningbo Hongning Hengtai

## Investors

- Vertex Ventures Southeast Asia & India (https://capitalatlas.ai/funds/vertex-ventures-southeast-asia-india) — Series A
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series A
- Ningbo Hongning Hengtai — Series A